101 related articles for article (PubMed ID: 15361263)
1. Obesity among outpatients with major depressive disorder.
Papakostas GI; Petersen T; Iosifescu DV; Burns AM; Nierenberg AA; Alpert JE; Rosenbaum JF; Fava M
Int J Neuropsychopharmacol; 2005 Mar; 8(1):59-63. PubMed ID: 15361263
[TBL] [Abstract][Full Text] [Related]
2. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine.
Papakostas GI; Petersen T; Denninger JW; Tossani E; Pava JA; Alpert JE; Nierenberg AA; Fava M
J Clin Psychopharmacol; 2004 Oct; 24(5):507-11. PubMed ID: 15349006
[TBL] [Abstract][Full Text] [Related]
3. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
[TBL] [Abstract][Full Text] [Related]
4. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.
Papakostas GI; Petersen T; Homberger CH; Green CH; Smith J; Alpert JE; Fava M
Ann Clin Psychiatry; 2007; 19(1):5-8. PubMed ID: 17453655
[TBL] [Abstract][Full Text] [Related]
5. Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetine.
Cassano P; Soares CN; Cohen LS; Lyster AK; Fava M
Arch Womens Ment Health; 2004 Jul; 7(3):167-71. PubMed ID: 15241662
[TBL] [Abstract][Full Text] [Related]
6. Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder.
Papakostas GI; Petersen T; Denninger JW; Montoya HD; Nierenberg AA; Alpert JE; Fava M
Ann Clin Psychiatry; 2003; 15(3-4):187-92. PubMed ID: 14971864
[TBL] [Abstract][Full Text] [Related]
7. Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder.
Lin CH; Chen CC; Wong J; McIntyre RS
J Affect Disord; 2014 Jun; 161():123-6. PubMed ID: 24751319
[TBL] [Abstract][Full Text] [Related]
8. Problem-solving ability and comorbid personality disorders in depressed outpatients.
Harley R; Petersen T; Scalia M; Papakostas GI; Farabaugh A; Fava M
Depress Anxiety; 2006; 23(8):496-501. PubMed ID: 16845662
[TBL] [Abstract][Full Text] [Related]
9. Treatment-resistant depression and Axis II comorbidity.
Petersen T; Hughes M; Papakostas GI; Kant A; Fava M; Rosenbaum JF; Nierenberg AA
Psychother Psychosom; 2002; 71(5):269-74. PubMed ID: 12207107
[TBL] [Abstract][Full Text] [Related]
10. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse.
Iovieno N; van Nieuwenhuizen A; Clain A; Baer L; Nierenberg AA
Depress Anxiety; 2011 Feb; 28(2):137-44. PubMed ID: 21284066
[TBL] [Abstract][Full Text] [Related]
11. Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment.
Farabaugh A; Sonawalla S; Johnson DP; Witte J; Papakostas GI; Goodness T; Clain A; Baer L; Mischoulon D; Fava M; Harley R
Ann Clin Psychiatry; 2010 Aug; 22(3):166-71. PubMed ID: 20680189
[TBL] [Abstract][Full Text] [Related]
12. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
13. Depression with atypical features and increase in obesity, body mass index, waist circumference, and fat mass: a prospective, population-based study.
Lasserre AM; Glaus J; Vandeleur CL; Marques-Vidal P; Vaucher J; Bastardot F; Waeber G; Vollenweider P; Preisig M
JAMA Psychiatry; 2014 Aug; 71(8):880-8. PubMed ID: 24898270
[TBL] [Abstract][Full Text] [Related]
14. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
Snedecor SJ; Botteman MF; Schaefer K; Sarocco P; Barry N; Pickard AS
J Ment Health Policy Econ; 2010 Mar; 13(1):27-35. PubMed ID: 20571180
[TBL] [Abstract][Full Text] [Related]
15. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine.
Papakostas GI; Petersen T; Lebowitz BD; Mischoulon D; Ryan JL; Nierenberg AA; Bottiglieri T; Alpert JE; Rosenbaum JF; Fava M
Int J Neuropsychopharmacol; 2005 Dec; 8(4):523-8. PubMed ID: 15877935
[TBL] [Abstract][Full Text] [Related]
16. Dysfunctional attitudes and personality disorder comorbidity during long-term treatment of MDD.
Farabaugh A; Mischoulon D; Schwartz F; Pender M; Fava M; Alpert J
Depress Anxiety; 2007; 24(6):433-9. PubMed ID: 17086540
[TBL] [Abstract][Full Text] [Related]
17. Body weight as a predictor of antidepressant efficacy in the GENDEP project.
Uher R; Mors O; Hauser J; Rietschel M; Maier W; Kozel D; Henigsberg N; Souery D; Placentino A; Perroud N; Dernovsek MZ; Strohmaier J; Larsen ER; Zobel A; Leszczynska-Rodziewicz A; Kalember P; Pedrini L; Linotte S; Gunasinghe C; Aitchison KJ; McGuffin P; Farmer A
J Affect Disord; 2009 Nov; 118(1-3):147-54. PubMed ID: 19269691
[TBL] [Abstract][Full Text] [Related]
18. The impact of medical comorbidity on acute treatment in major depressive disorder.
Iosifescu DV; Nierenberg AA; Alpert JE; Smith M; Bitran S; Dording C; Fava M
Am J Psychiatry; 2003 Dec; 160(12):2122-7. PubMed ID: 14638581
[TBL] [Abstract][Full Text] [Related]
19. Relief of depression and pain improves daily functioning and quality of life in patients with major depressive disorder.
Lin CH; Yen YC; Chen MC; Chen CC
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Dec; 47():93-8. PubMed ID: 23989033
[TBL] [Abstract][Full Text] [Related]
20. Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction.
Goldstein DJ; Rampey AH; Potvin JH; Masica DN; Beasley CM
J Clin Psychiatry; 1993 Aug; 54(8):309-16. PubMed ID: 8253699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
